Publikationen von Chefarzt Dr. Dr. Heinz Dürk

  1. Kinetics of Renal Function during Induction in Newly Diagnosed Multiple Myeloma: Results of Two Prospective Studies by the German Myeloma Study Group DSMM.
    Bachmann, F.; Schreder, M.; Engelhardt, M.; Langer, C.; Wolleschak, D.; Mügge, L.O.; Dürk, H.; Schäfer-Eckart, K.; Blau, I.W.; Gramatzki, M.; Liebisch, P.; Grube, M.; v Metzler, I.; Bassermann, F.; Metzner, B.; Röllig, C.; Hertenstein, B.; Khandanpour, C.; Dechow, T.; Hebart, H.; Jung, W.; Theurich, S.; Maschmeyer, G.; Salwender, H.; Hess, G.; Bittrich, M.; Rasche, L.; Brioli, A.; Eckardt, K.-U.; Straka, C.; Held, S.; Einsele, H.; Knop, S.
    Cancers 2021, 13, 1322-1335
  2. Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial.
    Röllig C, Serve H, Noppeney R, Hanoun M, Krug U, Baldus CD, Brandts CH, Kunzmann V, Einsele H, Krämer A, Müller-Tidow C, Schäfer-Eckart K, Neubauer A, Burchert A, Giagounidis A, Krause SW, Mackensen A, Aulitzky W, Herbst R, Hänel M, Frickhofen N, Kullmer J, Kaiser U, Kiani A, Link H, Geer T, Reichle A, Junghanß C, Repp R, Meinhardt A, Dürk H, Klut IM, Bornhäuser M, Schaich M, Parmentier S, Görner M, Thiede C, von Bonin M, Platzbecker U, Schetelig J, Kramer M, Berdel WE, Ehninger G.
    Leukemia (2021). Epub ahead of print.
  3. First Interim Results of NIS Optimob - Nationwide Trial of Mobilization and Collection of Hematopoietic Stem and Progenitor Cells in Multiple Myeloma and Lymphoma Patients.
    M Bittrich, V Vucinic, M Grube, M Hentrich, M de Wit, Ch Kunz, B Metzner, A Humpe, A Stoltefuß, A Rank, K Movassaghi, A Kiani, C Khandanpour, M Schmidt-Hieber, F Hartmann, N Kröger
    Bone Marrow Transplant 55, 181–714 (2020) P677.
  4. NIS OPTIMOB: First results of a systemic evaluation of mobilization and collection of hematopoietic stem and progenitor cells in clinical practice in patients with multiple myeloma (MM) and lymphoma.
    V. Vucinic, M. Bittrich, K. Movassaghi, M. Grube, K. Kriegsmann, H. Dürk, C. Kunz, D. Wehler, B. Metzner, A. Humpe, N. Kröger.
    Transfus Med Hemother 2020;47(suppl 1): PS-3-1.
  5. NIS OPTIMOB: First results of real-world data on mobilization and collection of hematopoietic stem and progenitor cells in patients with multiple myeloma and lymphoma in Germany.
    Bittrich M., Movassaghi K., Vucinic V., Grube M., Kriegsmann K., Durk H.A., Kunz C., Wehler D, Metzner B., Hentrich M., de Wit M., Schmidt-Hieber M., Humpe A., Kroger N.     Oncology Research and Treatment 43, Suppl. 4, Abstr. 322 (2020).
  6. A. Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trial. Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trial.
    Schmitz C, Rekowski J, Müller SP, Hertenstein B, Franzius C, Ganser A, Bengel FM, Kroschinsky F, Kotzerke J, La Rosée P, Freesmeyer M, Hoeffkes HG, Hertel A, Behringer D, Mesters R, Weckesser M, Mahlmann S, Haberkorn U, Martens U, Prange-Krex G, Brenner W, Giagounidis A, Moeller R, Runde V, Sandmann M, Hautzel H, Wilop S, Krohn T, Dürk H, Heike M, Alashkar F, Brinkmann M, Trenn G, Wacker D, Kreisel-Büstgens C, Bernhard H, Heil G, Larisch R, Kurch L, Jöckel KH, Hoelzer D, Klapper W, Boellaard R, Dührsen U, Hüttmann.
    Hematological Oncology. (2020);38:244–256
  7. German Myeloma Study Group: Bortezomib, lenalidomide, and dexamethasone (VRD) is superior to lenalidomide, adriamycin, and dexamethasone (RAD) prior to risk-adapted transplant in newly diagnosed myeloma.
    Stefan Knop, Christian Langer, Monika Martha Engelhardt, Florian Bassermann, Martin Schreder, Lars-Olof Muegge, Kerstin Schaefer-Eckart, Igor W. Blau, Denise Wolleschak, Julia Reusch, Ivana von Metzler, Bernd Metzner, Tobias Dechow, Bernd Hertenstein, Heinz Duerk, Sebastian Theurich, Thomas Stuebig, Jan Kroenke, Swantje Held, Hermann Einsele.
    Journal of Clinical Oncology 38, no. 15_suppl (2020) 8521-8521.
  8. Donor-cell leukemia with novel genetic features 2 years after sex-mismatched T cell-depleted haploidentical stem cell transplantation.
    Luber V, Lutz M, Thiede C, Haferlach C, Dürk HA, Einsele H, Grigoleit GU, Mielke S.
    Ann Hematol. 2020 Apr;99(4):899-901
  9. Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trials.
    Straka C, Knop S, Vogel M, Müller J, Kropff M, Metzner B, Langer C, Sayer H, Jung W, Dürk HA, Salwender H, Wandt H, Bassermann F, Gramatzki M, Rösler W, Wolf HH, Brugger W, Fischer T, Liebisch P, Engelhardt M, Einsele H.
    Eur J Haematol. 2019 Sep;103(3):255-267.
  10. Lenalidomide, Adriamycin and Dexamethasone (RAD) Versus Bortezomib, Lenalidomide and Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) - Post-Induction Response and MRD Results By Flow Cytometry and NGS from a Phase 3 Randomized Controlled Clinical Trial (RCT).
    Thomas Stübig, Christian Langer, Monika Engelhardt, Lars-Olof Mügge, Florian Bassermann, Martin Schreder, Kerstin Schäfer-Eckart, Igor Wolfgang Blau, Denise Wolleschak, Albrecht Reichle, Ivana Metzler, Bernd Metzner, Christoph Rollig, Bernd Hertenstein, Heinz Dürk, Harald Biersack, Helge Menzel, Tobias Dechow, Jan Schleicher, Martin Gramatzki, Tim H. Brümmendorf, Stephan Fuhrmann, Max Bittrich, Franziska Appelt, Martina Müller, Jan Krönke, Julia Reusch, Christian Schmidt, Monika Brüggemann, Swantje Held, Stefan Knop, Hermann Einsele.
    Blood 2018; 132 (Supplement 1): 1979
  11. Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial.
    Winston DJ, Mullane KM, Cornely OA, Boeckh MJ, Brown JW, Pergam SA, Trociukas I, Žák P, Craig MD, Papanicolaou GA, Velez JD, Panse J, Hurtado K, Fernsler DA, Stek JE, Pang L, Su SC, Zhao Y, Chan ISF, Kaplan SS, Parrino J, Lee I, Popmihajlov Z, Annunziato PW, Arvin A; V212 Protocol 001 Trial Team.
    Lancet. 2018 May 26;391(10135):2116-2127
  12. Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial.
    Einsele H, Engelhardt M, Tapprich C, Müller J, Liebisch P, Langer C, Kropff M, Mügge LO, Jung W, Wolf HH, Metzner B, Hart C, Gramatzki M, Hertenstein B, Pfreundschuh M, Rösler W, Fischer T, Maschmeyer G, Kanz L, Hess G, Jäger E, Bentz M, Dürk HA, Salwender H, Hebart H, Straka C, Knop S.
    Br J Haematol. 2017;179(4):586-597
  13. Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma.
    Einsele H, Knop S, Vogel M, Müller J, Kropff M, Metzner B, Langer C, Sayer H, Jung W, Dürk HA, Salwender H, Wandt H, Bassermann F, Gramatzki M, Rösler W, Wolf HH, Brugger W, Engelhardt M, Fischer T, Liebisch P, Straka C.
    Leukemia. 2017 Jun;31(6):1463-1466
  14. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
    Röllig C, Serve H, Hüttmann A, Noppeney R, Müller-Tidow C, Krug U, Baldus CD, Brandts CH, Kunzmann V, Einsele H, Krämer A, Schäfer-Eckart K, Neubauer A, Burchert A, Giagounidis A, Krause SW, Mackensen A, Aulitzky W, Herbst R, Hänel M, Kiani A, Frickhofen N, Kullmer J, Kaiser U, Link H, Geer T, Reichle A, Junghanß C, Repp R, Heits F, Dürk H, Hase J, Klut IM, Illmer T, Bornhäuser M, Schaich M, Parmentier S, Görner M, Thiede C, von Bonin M, Schetelig J, Kramer M, Berdel WE, Ehninger G; Study Alliance Leukaemia.
    Lancet Oncol. 2015 Dec;16(16):1691-9.
  15. Bendamustine Plus Rituximab (B-R) Versus CHOP Plus Rituximab (CHOP-R) As First-Line Treatment in Patients with Indolent and Mantle Cell Lymphomas (MCL) – 7 Year Updated Results from the StiL NHL1 Study.
    Mathias J. Rummel, Andreas Viardot, Richard Greil, Bernd Hertenstein, Christian Lerchenmüller, Arnold Ganser, Manfred Reeb, Ulrich Kaiser, Christina Balser, Georg Maschmeyer, Heinz Dürk, Georg Schliesser, Tobias Gaska, Jan Dürig, Axel C. Matzdorff, Rudolf Weide, Axel Hinke, Wolfgang Blau, Alexander Burchardt, Frank Kauff, Jürgen Barth, Wolfram Brugger.
    Blood 124 (21):  Abstract 4407; (2014).
  16. Therapy of Acquired Aplastic Anemia (AA) with Rabbit Antithymocyte Globulin (rATG): A Retrospective Analysis by the Working Group on Non-Malignant Disorders of Hematopoiesis of the German Society of Hematology and Oncology (DGHO).
    Britta Höchsmann, Christiane Neher, Ulrich Germing, Janne Vehreschild, Juliane Eggermann, Dietrich Braumann, Bernd Hertenstein, Anke Franzke, Karin Mayer, Paul La Rosée, Stefan Wilop, Karl-Heinz Pfluege, Hans-Josef Weh, Bernd Gruhn, Alfred Leipold, Mark Ringhoffer, Heinz A. Duerk, Kumar Sinah, Aristoteles Giagounidis, Hubert Schrezenmeier.
    Blood 118 (21) Abstract 3434 (2010).
  17. Bendamustine Plus Rituximab Followed By Rituximab Maintenance for Patients with Untreated Advanced Follicular Lymphomas. Results from the StiL NHL 7-2008 Trial (MAINTAIN trial) (ClinicalTrials.gov Identifier: NCT00877214).
    Mathias J. Rummel, Andreas Viardot, Richard Greil, Bernd Hertenstein, Christian Lerchenmüller, Arnold Ganser, Manfred Reeb, Ulrich Kaiser, Christina Balser, Georg Maschmeyer, Heinz Dürk, Georg Schliesser, Tobias Gaska, Jan Dürig, Axel C. Matzdorff, Rudolf Weide, Axel Hinke, Wolfgang Blau, Alexander Burchardt, Frank Kauff, Jürgen Barth, Wolfram Brugger
    Blood 124 (21): Abstract 3052 (2014).
  18. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
    Mathias J Rummel, Norbert Niederle, Georg Maschmeyer, G Andre Banat, Ulrich von Grünhagen, Christoph Losem, Dorothea Kofahl-Krause, Gerhard Heil, Manfred Welslau, Christina Balser, Ulrich Kaiser, Eckhart Weidmann, Heinz Dürk, Harald Ballo, Martina Stauch, Fritz Roller, Juergen Barth, Dieter Hoelzer, Axel Hinke, Wolfram Brugger, on behalf of the Study group indolent Lymphomas (StiL).
    The Lancet; 381:1203 – 1210 (2013).
  19. Final results of a prospective, multicentre, randomized trial comparing 1, 3 or 6 infusions of Rituximab combined with 6 cycles of CHOP chemotherapy in untreated patients with advanced follicular lymphoma.
    McClanahan F, Hielscher T, Rieger M, Hensel M, Bentz M, Schmidt-Wolf I, Käbisch A, Salwender H, Dürk H, Staiger H, Mandel T, Neben K, Hillengass J, Leo E, Krämer A, Ho AD, Witzens-Harig M.
    American Journal of Hematology 2012; 87(10): E68-71.
  20. Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study.
    Mathias J. Rummel, Norbert Niederle, Georg Maschmeyer, Andre G. Banat, Ulrich von Gruenhagen, Christoph Losem, Dorothea Kofahl-Krause, Gerhard Heil, Manfred Welslau, Christina Balser, Ulrich Kaiser, Eckhart Weidmann, Heinz A. Duerk, Harald Ballo, Martina Stauch, Juergen Barth, Axel Hinke, Wolfram Brugger, Study Group Indolent Lymphomas (StiL).
    ASCO J Clin Oncol; 30:(suppl; abstr 3) (2012).
  21. Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients.
    Brunnberg U, Mohr M, Noppeney R, Dürk HA, Sauerland MC, Müller-Tidow C, Krug U, Koschmieder S, Kessler T, Mesters RM, Schulz C, Kosch M, Büchner T, Ehninger G, Dührsen U, Serve H, Berdel WE.
    Ann Oncol. 23:990-6 (2011).
  22. Sabarubicin (SABA) in combination with cisplatin (DDP): Maximum tolerated dose (MTD) evaluation (phase I step) followed by a phase II step in patients (pts) with small cell lung cancer-extensive disease (SCLC-ED).
    O. A. Cornely, J. Wolf, K. M. Josten, T. Mueller, H. A. Duerk, W. Neumeister, M. Sebastian, C. Simonelli, A. Capriati, M. Karthaus, for the SABA with DDP Working Group.
    J Clin Oncol 28:15s, (suppl; abstr 7048) (2010).
  23. Sabarubicin (SABA) in Kombination mit Cisplatin (DDP): Maximal tolerable Dosis (MTD) in einer Phase I/II-Studie bei Patienten mit kleinzelligen Bronchialkarzinom (SCLC-ED).
    Cornely, O.A.; Wolf, J.; Josten, K.M.; Müller, T.; Dürk, H.A.; Neumeister, W.;Sebastian, M; Schroeder, M.; Simonelli, C.; Capriati, A.; Karthaus, M.
    Jahrestagung der deutschen, österreichischen und schweizerischen Gesellschaften für Hämatologie und Onkologie 2010 · Abstract: A-275-0022-00245 (2010).
  24. Final results of a prospective, multicentre, randomized trial comparing 1, 3 or 6 infusions of Rituximab combined with 6 cycles of CHOP chemotherapy in untreated patients with advanced follicular lymphoma.
    McClanahan, Fabienne, Hielscher, Thomas, Rieger, Michael; Hensel, Manfred; Bentz, Martin;Schmidt-Wolf, Ingo; Käbisch, Andreas; Salwender, Hans; Dürk, Heinz; Staiger, Hans-Jürgen; Mandel, Thomas; Neben, Kai; Hillengass, Jens; Ho, Anthony; Leo, Eugen; Kraemer, Alwin; Witzens-Harig, Mathias
    Leukemia and Lymphoma (2010).
  25. Induction therapy by Ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamycin: interim analysis of a randomized phase II trial in elderly patients with acute myeloid leukemia.
    Uta Brunnberg, Michael Mohr, Richard Noppeney, Heinz A. Dürk, Cristina Sauerland, Carsten Müller-Tidow, Utz Krug, Steffen Koschmieder, Torsten Kessler, Rolf M. Mesters, Christiane Schulz, Thomas Büchner, Gerhard Ehninger, Ulrich Dührsen, Hubert Serve, Wolfgang E. Berdel.
    Blood (ASH Annual Meeting Abstracts), Nov 2010;116: # 335 (2010).
  26. ß2-Micro-globulin detection: different assays with different normal ranges. the impact on multiple myeloma prognostic staging system.
    H. Dürk, A. Rietschel-Klein, G. Walther-Wenke, T. Brinkmann.
    Clin Chem Lab Med 2009; 47, Special Supplement (2009).
  27. How Much Rituximab Do We Need: A Multicenter, Randomized Trial Comparing 1, 3 or 6 Infusions of Rituximab Combined with 6 Cycles of CHOP Chemotherapy in Untreated Patients with Advanced Follicular Lymphoma (HD2000-Trial).
    Fabienne McClanahan, Thomas Hielscher, Michael Rieger, Manfred Hensel, Martin Bentz, Ingo Schmidt-Wolf, Andreas Kaebisch, Hans-Jürgen Salwender, Heinz Dürk, Hans Juergen Staiger, Thomas Mandel, Kai Neben, Jens Hillengass, Anthony D. Ho, and Mathias Witzens-Harig.
    Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 2687 (2009).
  28. Velcade, Intravenous Cyclophosphamide and Dexamethasone (VCD) Induction for Previously Untreated Multiple Myeloma (German DSMM XIa Trial).
    Hermann Einsele, Peter Liebisch, Christian Langer, Martin Kropff, Hannes Wandt, Wolfram Jung, Nikolaus Kröger, Monika Engelhardt, Helmut Ostermann, Lars-Olof Mügge, Hans-Heinrich Wolf, Christina Hart, Bernd Metzner, Martin Kaufmann, Martin Gramatzki, Bernd Hertenstein, Thomas Fischer, Katja Weisel, Gottfried Dölken, Wolfram Brugger, Hella Gollasch, Georg Maschmeyer, Michael Pfreundschuh, Norbert Schmitz, Orhan Sezer, Else Heidemann, Elke Jäger, Christoph Kahl, Alexander Kiani, Tobias Dechow, Wolf Rösler, Jan Philipp Simon, Heinz Dürk, Karl Heinz Pflüger, Martin Bentz, Georg Hess, Hans-Guenther Mergenthaler, Christian Straka, Dirk Hempel, Hans-Jürgen Salwender, Günter Fingerle-Rowson, and Stefan Knop.
    Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 131 (2009).
  29. Bendamustine Plus Rituximab Is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients with Advanced Follicular, Indolent, and Mantle Cell Lymphomas: Final Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany)
    Mathias J Rummel, Norbert Niederle, Georg Maschmeyer, Andre Banat, Ulrich von Gruenhagen, Christoph Losem, Gerhard Heil, Manfred Welslau, Christina Balser, Ulrich Kaiser, Harald Ballo, Eckhart Weidmann, Heinz A Duerk,, Dorothea Kofahl-Krause, Fritz Roller, Juergen Barth, Dieter Hoelzer, Axel Hinke,Wolfram Brugger.
    Blood (ASH Annual Meeting Abstracts) 114: Abstract 405 (2009).
  30. Bendamustine Plus Rituximab Versus CHOP Plus Rituximab in the First-Line-Treatment of Patients with Follicular, Indolent and Mantle Cell Lymphomas: Results of a Randomized Phase III Study of the Study Group Indolent Lymphomas (StiL).
    Mathias J Rummel, Ulrich von Gruenhagen, Norbert Niederle, Harald Ballo, Eckhart Weidmann, Manfred Welslau, Gerhard Heil, Christina Balser, Heinz A Duerk, Martina Stauch, Dorothea Kofahl-Krause, Ulrich Kaiser, Wolfgang Knauf, and Wolfram Brugger.
    Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 2596 (2008).
  31. Peg-filgrastim (peg-f) on day 4 of (R-)CHOP-14 chemotherapy is superior to day 2 in elderly patients with diffuse large B-cell-lymphoma (dlbcl): Results of a randomized trial of the German High-Grade Non-Hodgkin-Lymphoma Study Group (DSHNHL).
    V. Pöschel, F. Hartmann, S. Zeynalova, C. Nickenig, M. Reiser, E. Lengfelder, H. Dürk, N. Murawski, J. Schubert, M. Löffler, M. Pfreundschuh.
    J Clin Oncol. 2007;25(Suppl 18): Abstract 19511 (2008).
  32. Bortezomib, Intravenous Cyclophosphamide and Dexamethasone (VelCD) for Previously Untreated Multiple Myeloma: An Interim Analysis of the German DSMM X Trial.
    S. Knop, P. Liebisch, H. Wandt, M. Kropff, V. Kunzmann, K. Weisel, H. Ostermann, M. Engelhardt, L. Trümper, N. Kroeger, B. Hennemann, M. Pfreundschuh et al.
    Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 2776 (2008).
  33. Endamustine Plus Rituximab Versus CHOP Plus Rituximab in the First-Line Treatment of Patients with Indolent and Mantle Cell Lymphomas - First Interim Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany).
    Mathias J. Rummel, U. von Gruenhagen, N. Niederle, F. Rothmann, H. Ballo, E. Weidmann, M. Welslau, G. Heil, H. Duerk, M. Stauch, C. Losem, A. Matzdorff, C. Balser, K. Schalk, D. Kofahl-Krause, U. Kaiser, W. Knauf, A. Banat, D. Hoelzer, W. Brugger on behalf of the StiL.
    Blood (ASH Annual Meeting Abstracts),2007; 110: 385 (2007).
  34. A phase II study of irinotecan (CTPT-11) and carboplatin in patients with limited disease small cell lung cancer (SCLC).
    Laack E, Thöm I, Krüll A, Engel-Riedel W, Müller Th, Meißner CH, Dürk H, Fischer J, Burholder I, Bokemeyer C.
    Lung Cancer. 2007 Aug;57(2):181-186.
  35. Maintenance Therapy for Multiply Myeloma with Particular Emphasis on Thalidomide
    Dürk H
    Onkologie 2006; 29:582-590.
  36. Bendamustine and rituximab act synergistically in vitro and are effective in the treatment of relapsed or refractory indolent and mantlecell lymphomas.
    Rummel M.J., Krüger S., Al-Bartan S.A., Welslau M., Hecker R., Kofahl-Krse D., Josten K.M., Dürk H.A., Rost A., Neise M., von Grünhagen U., Schalk K., Stauch M., Ballo H.E., Banat A., Knauf W., Niederle N., Hansmann M.L., Hoelzer D., Mitrou P.S.
    Onkologie 2005; 28 (Suppl. 3): page 94, abstract 280.
  37. Pilotstudie mit Docetaxel and Cisplatin als Erstlinienchemotherapie beim metastasierten Ösophaguskarzinom.
    Andritzky B., Dürk H., Borkholder I., Edler L., Schuch G., Boeters I., Görn M., Popp J., Lipp R., Horst H., Hossfeld D. K., Bokemeyer C., Laack E.
    04.10.2005 Gemeinsame Jahrestagung der Deutschen, Österrreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie
    Onkologie 2005 (Suppl. 3) Nr. 745, 28
  38. Docetaxel and Cisplatin as First-Line Treatment for Patients with Metastatic Esophageal Cancer: A Pilot Study.
    Laack E, Andritzky B, Dürk H, Burkholder I, Edler L, Schuch G, Boeters I, Görn M, Lipp R, Horst H, Popp J, Hossfeld DK.
    Onkologie 2005; 28: 647-650.
  39. Bendamustine plus Rituximab is effective and has a favorable toxicity profile in the treatment of Mantle Cell and Low-Grade-Non-Hodgkin’s Lymphoma.
    Rummel M, Al-Batran S, Kim S, Welslau M, Hecker R, Kofahl-Krause D, Josten K, Dürk H, Rost A, Neise M, Grünhagen von U, Chow K, Hansmann M, Hoelzer D, Mitrou P.
    J Clin Oncol, 23, 3383-3389 (2005).
  40. How Much Rituximab Do We Need: A Multicenter, Randomized Trial Comparing 1, 3 or 6 Infusions of Rituximab Added to 6 Cycles of CHOP Chemotherapy in Untreated Patients with Advanced Follicular Non-Hodgkins Lymphoma (HD2000-Trial).

  41. Manfred Hensel, Lars Scheuer, Hans Salwender, Juergen Finke, Dieter Buerkle, Heinz Albert Duerk, Andreas Kaebisch, Ralf Naumann, Hans-Juergen Staiger, Ingo Schmidt-Wolf, Martin Kornacker, Eugen Leo, Joseph Fischer, and Anthony D. Ho
    Blood (ASH Annual Meeting Abstracts), Nov 2004; 104: 4584

  42. Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group.
    Laack E, Dickgreber N, Müller T, Knuth A, Benk J, Lorenz C, Gieseler F, Dürk H, Engel-Riedel W, Dalhoff K, Kortsik C, Graeven U, Burk M, Dierlamm T, Welte T, Burkholder I, Edler L, Hossfeld DK; German and Swiss Lung Cancer Study Group
    J Clin Oncol.22(12):2348-56 (2004).
  43. P-604 Multicenter German/French phase-II trial of induction-CTx followed by concurrent CTx/RTx +/- surgery (S) in locally far advanced inoperable non-small-cell lung cancer (NSCLC) stages IIIA(N2) and IIIB - preliminary results of toxicity and efficacy including a newer induction-CTx regimen.
    Thomas Gauler; Wilfried Ernst-Erich Eberhardt; Cecile Le Pechoux; Christoph Pottgen; Dominique Grunenwald Stephan Bildat; Georgios Stamatis; Heinz-Albert Duerk; Martin Stuschke; Thierry Lechevalier.
    Lung Cancer 41, S244 (2003).
  44. Docetaxel and carboplatin as second-line chemotherapy for metastatic non-small cell lung cancer.
    Laack E, Dierlamm T, Knuffmann C, Popp J, Schmid B, Dürk H, Wacker-Backerhaus G, Zeller W, Verpoort K, Fiedler W, Kurt Hossfeld D.
    Lung Cancer, 36, 303-7 (2002).
  45. Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer: a phase II trial.
    Laack E, Mende T, Dürk H, Kneba M, Dickgreber N, Welte T, Müller T, Scholtze J, Graeven U, Jasiewicz Y, Edler L, Hossfeld DK.
    Eur J Cancer, 38, 654-60 (2002).
  46. Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer: a phase II trial.
    Laack E, Mende T, Benk J, Chemaissani A, Scholtze J, Lorenz C, Niestroy A, Dahlhoff K, Müller T, Walter T, Dürk H, Edler L, Hossfeld DK.
    Eur J Cancer, 37, 583-90 (2001).
  47. Triple combination of mitoxantrone, topotecan, araC (MTC) in relaped or refractory AML.
    Bergmann L, Heil G, Denzlinger C, Raghavachar A, Dürk H, Doehner H, Einsele H, Ganser A, Hoelzer D, Hoechsmann B.
    Proc. of ASCO 21, Abstract No: 1081 (2002).
  48. A randomized study of zoledronate versus control in patients with multiple myeloma stage I.
    Freund M, Sezer O., Ammon A, Aldaoud A, Aulitzky W, Brudler O, Derigs H, Dürk H, Einsele H, Emmerich B, Fischer J, Fuchs R, Haus U, Herold M, Hoffmann R, Kaiser U, Kleeberg U, Maintz C, Mittermüller J, Niederwieser D, Nowrousian M, Pasold R, Peest D, Pflüger K, Rohrberg R, Schmidt-Wolf I, Seipelt G, Weinkauf B, Wolf H, Wolf HH, and Wörmann H.
    Onkologie (24 (S 6)), 86 #331 (2001).
  49. A Multicentre Trial with Topotecan, Mitoxantrone and Cytarabine in Patients with Relapsed or Refractory AML or CML in Blast Crisis - Interim Results.
    Hoechsmann B, Doehner H, Ganser A, Heil G, Denzlinger C, Einsele H, Dürk H, Raghavachar A, Hoelzer D, Bergmann L.
    Blood, 98, Number 11 (Part 2) #4564 (2001).
  50. A multicenter trial with topotecan, mitoxantrone and cytarabine in patients with relapsed or refractory acute myeloid leukemia or blast crisis in chronic myeloid leukemia - interim results.
    Hoechsmann B, Döhner H, Ganser A, Heil G, Denzlinger C, Einsele H, Raghavachar A, Dürk H, Hoelzer D, Bergmann L.
    Onkologie 24 (6) #141 (September 2001).
  51. Mitoxantrone, Topotecan and Cytosin-Arabinoside (MTC) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Chronic Myeloid Leukemia in Blast Crisis - Interim Results.
    Bergmann L, Manegold A, Heil G, Ganser A, Einsele H, Knop S, Dürk H, Raghavachar A, Dohner H, Hoechsmann B.
    Proc. of ASCO 20, #1205 (2001).
  52. A pilot-study with gemcitabine (GEM), vinorelbine (VNR) and cisplatin (P) in the treatment of advanced non-small cell lung cancer (NSCLC).
    Laack E, Mende T, Dürk H, Kneba M, Dickgreber N, Müller T, Scholtze J, Graeven U, Hirth M, Hossfeld DK.
    Ann. Oncol., Vol 11, Suppl.4, 115, #523P (2000).
    Bericht von der 41. Jahrestagung der American Society of Hematology
    in New Orleans vom 03. – 06.12.1999, Dürk H
    www.myelom.de/therapie/medizin/ash.htm
  53. Leukozytose bei starken Rauchern.
    Dürk H, Saal JG
    Praxis med 9: 58 (1997).
  54. Manual Rheumatologie
    Saal JG, Dürk H, Kötter I (Hrsg),
    Chapman and Hall (1997).
  55. Nagelfalzvaskulitis unter Methotrexat-Therapie bei rheumatoider Arthritis.
    Günaydin I, Kötter I, Dürk H, Saal JG
    Akt. Rheumatol 22: 66 - 68 (1997).
  56. Manual der Rheumatologie.
    Saal JG, Dürk H, Kötter I Hrsg.: Saal JG, Dürk H, Kötter I.
    Churchill Livingstone     (1997).
  57. Erosive arthritis and posterior uveitis in Behçet’s disease: treatment with interferon a and interferon g.
    Kötter, I., Dürk, H., Eckstein, A., Zierhut, M., Fierlbeck, G., Saal, J.G.
    Clin Exp Rheum 14: 313-315 (1996).
  58. Morbus Behcet: Epidemiologie, Verlauf, therapeutische Optionen.
    Kötter I, Dürk H, Saal JG, Eckstein A, Zierhut M, Fierlbeck G.
    DMW 121: 382 - 388 (1996).
  59. Therapy of Behcet’s disease.
    Kötter I, Dürk H, Saal JG, Eckstein A, Fierlbeck G, Pleyer Ü, Zierhut M.
    German J Ophthalmol 5: 92 - 97 (1996).
  60. Mercury exposure from dental amalgam fillings in the etiology of primary fibromyalgia: A pilot study.
    Kötter I, Dürk H, Saal JG, Kroiher A, Schweinsberg F.
    Rheumatol. 22, 2194 - 2195 (1995).
  61. Diagnostik der pulmonalen Aspergillose mittels Thorax-Röntgen (Amber-Technik) und hochauflösender Computertomographie.
    Torkler C, Huppert P, Dürk H, Claussen C.
    Der Radiologe. 628 (1995).
  62. Selenium (Se) levels in fibromyalgia (FM)
    Kötter I, Dürk H, Schweinsberg F, Saal JG.
    J. Musculo Skeletal Pain; 3 ; (S 1) : 46 (1995).
  63. Mercury exposure from dental amalgam fillings in the etiology of primary FM: a pilot study.
    Kötter I, Dürk H, Sall JG, Kroier A, Schweinsberg F.
    J Rheumatol 22: 2194 - 2495 (1995).
  64. Cryoglobulinemia and chronic hepatitis C elimination of the virus is not a precondition for response to a-Interferon.
    Glück Th, Dürk H, Kötter I, Zimmermann C, Saal JG.
    Med. Klinik 90: 674 - 681 (1995).
  65. Sacroiliitis in sarcoidosis. Case reports and review of the literature.
    Kötter I, Dürk H, Saal JG.
    Clin Rheumatol 14: 695 - 701 (1995).
  66. Behçet’s disease. Epidemiology and eye manifestations in german and mediterranian patients.
    Zierhut M, Saal J, Pleyer U, Kötter I, Dürk H, Fierlbeck G.
    German J Ophthalmol 4: 246-251 (1995).
  67. Eosinophilia-myalgia syndrome: Findings at MR imaging and proton spectroscopy of the lower leg.
    Schick F, Duda S, Dürk H, Bunse M, Lutz O, Claussen CD.
    MR Imaging 12: 513 - 522 (1994).
  68. Interferon a in the treatment of Behcet’s disease with erosive arthritis and posterior uveitis - A case report.
    Kötter I, Dürk H, Saal JG, Pleyer U, Zierhut M, Fierlbeck G.
    Clin Rheumatol 13, 398 (1994).
  69. Rationale Labordiagnostik in klinischer Immunologie und Rheumatologie.
    Saal JG, Dürk H.
    Internist 35, 633 – 640 (1994).
  70. Prolactin (PRL) levels in primary fibromyalgia (FM).
    Kötter I, Matter F, Dürk H, Saal JG.
    Arthritis Rheum, Suppl. (1994).
  71. Therapie hyperostotischer Osteoarthropathien mit 3-Amino-1hydroxypropyliden1-1-Bisphosphonat (APD).
    Hebart H, Dürk H, Kötter I, Sökler M, Saal JG.
    Z Rheumatol 53 Suppl., 124 (1994).
  72. Therapie der Hepatitis C-assoziierten Kryoglobulinanämie Typ II mit a-Interferon.
    Dürk H, Glück Th, Kötter I, Saal JG.
    Z Rheumatol 53 Supp., 39, V156 (1994).
  73. Induktion einer seropositiven chronischen Polyarthritis durch a-Interferon.
    Kötter I, Dürk H, Saal JG.
    Z Rheumatol 53 Supp., 31 (1994).
  74. Prolactin levels in primary fibromyalgia.
    Kötter I, Matter F, Weiß EM, Dürk H, Saal JG.
    Z Rheumatol 53, 109 (1994).
  75. Mercury, lead and selenium in primary fibromyalgia.
    Kötter I, Kroiher A, Schweinsberg F, Dürk H, Saal JG.
    Scand J Rheumatol 23, Suppl. 98, 38 (1994).
  76. Epidemiology and ocular manifestations of Behçet’s disease.
    Saal JG, Zierhut M, Pleyer U, Kötter I, Dürk H.
    Invest Ophthalmology Visual Science 35, 2098 (1994).
  77. Behçet’s disease in 39 german and mediteranean patients.
    Kötter I, Dürk H, Fierlbeck G, Pleyer U, Zierhut M, Saald JG.
    Godeau P, Wechsler B (eds.): Behçet’s disease Elsevier Science Publishers, Amsterdam, 197 - 200 (1993).
  78. Skelettmanifestationen der primären Amyloidose: Fallbeschreibung und Literaturübersicht.
    Dürk H, Kötter I, Saal JG. In: Pesch HJ, Stöß H, Kummer BS (Hrsg.): Osteologie aktuell Bd. VII. Springer Verlag, Berlin, 650 – 654 (1993).
  79. Behçet's disease and myositis - a rare association.
    Lingenfelser Th, Duerk H, Knorr M, Stevens A, Saal J R.
    Ann Intern Med 1992; 116:651-53
  80. Sacroiliitis bei Sarkoidose. 2 Fallbeschreibungen.
    Kötter I, Dürk H, Saal JG.
    Z Rheumatol 51, Suppl. 2, 90 (1992).
  81. L-Tryptophan associated eosinophilia myalgia Syndrome (EMS). Course and treatment with Cyclosporin A (CSA).
    Dürk H, Kötter I, Saal JG.
    Br J Rheumatol 31, Suppl 2, 218 (1992).
  82. Skelettmanifestationen der primären Amyloidose: Fallbeschreibung und Literaturübersicht.
    Dürk H, Saal JG.
    Osteologie 1, Suppl. 1, 16 (1992).
  83. Acetylene, a mammalian metabolite of 1,1,1-trichloroethane.
    Dürk H, Poyer JL, Klessen Ch, Frank H.
    J Biol Chem 286, 353 – 356 (1992).
  84. Acetylene, a mammalian metabolite of 1,1,1-trichloroethane.
    Dürk H, Poyer JL, Klessen Ch, Frank H.
    Biochem J 286, 353 - 356 (1992).
  85. Sulphasalazintherapie bei Patienten mit HLA B 27-pos. und HLA B 27-negativer Oligoarthritis und rheumatoider Arthritis.
    Dürk H, Kötter I, Saal JG.
    Klin Wochenschr 69, Suppl. XXIII, 70 (1991).
  86. Keratomalazie bei rheumatoider Arthritis: immunhistologische und enzymhistochemische Untersuchungen.
    Saal JG, Fritz P, Zymela B, Zierhut M, Dürk H, Müller C, Pleyer U, Thiel HJ.
    Z Rheumatol 50, 151 – 159 (1990).
  87. Reductive metabolism of 1,1,1-trichloroethane.
    Dürk H, Klessen Ch, Frank H.
    Arch Pharmacol 341, Suppl. R 11, 42 (1990).
  88. Immunohistological studies on the pathophysiology of peripheral corneal ulcers (PCU) in rheumatoid arthritis (RA).
    Dürk H, Fritz P, Zierhut M, Müller C, Zymela B, Saal JG.
    Clin Exp Rheumatol 8 S: 22 (1990).
  89. Non-Hodgkin’s lymphoma presenting as knee monoarthritis with a popliteal cyst.
    Haase KK, Dürk H, Baumbach A, Saal JG, Wehrmann M.
    J Rheumatol 17, 1252 - 1254 (1990).
  90. Panzytopenie bei niedrig dosierter oraler Methotrexat-Therapie der Arthritis psoriatica.
    Kohler S, Neumann J, Dürk H, Saal J, Müller GA.
    DMW 114, 1286 – 1288 (1989).
  91. Zerebrale Manifestation bei einem seit 20 Jahren bestehenden Plasmozytom.
    Haase KK, Ickrath O, Dürk H, Elmer K, Steinke B.
    Tumor Diagnostik Ther 10, 131 - 180 (1989).
  92. Bovine cartilage and marrow extract.
    Berg PA, Dürk H, Saal J, Hopf G.
    The Lancet I, 1275 (1989).
  93. Nephrotic syndrome after injections of bovine cartilage and marrow extract (Arumalon).
    Dürk H, Haase K, Saal J, Becker W, Berg PA.
    The Lancet I, 614 (1989).
  94. Sternoclavicular destructive arthropathy in colitis ulcerosa: Effects of radiotherapie with fast electrons.
    Saal JG, Dürk H.
    Rev Rheumatism 55, 855 (1988).
  95. Fatty acids in liver microsomal lipids of rats exposed to hypoxia, tetrachloromethane, or both.
    Frank H, Dürk H, Thiel D.
    Biochem Biophys Acta 922, 54 - 61 (1987).
  96. Tetrachloromethane metabolism in vivo under normoxia and hypoxia. Biochemical and histopathological effects relative to alkane exhalation.
    Dürk H, Klessen C, Frank H.
    Arch Toxicol 60, 115 – 121 (1987).
  97. Carbon tetrachloride metabolism in vivo and exhalation of volatile alkanes: dependance upon oxygen partial pressure.
    Dürk H, Frank H.
    Toxicology 30, 249 - 257 (1984).
  98. Binding of trichloromethylradicals to lipids of endoplasmic reticulum during tetrachloromethane metabolism.
    Link B, Dürk H, Thiel D, Frank H.
    Biochem J 223, 577 - 586 (1984).
  99. Determination of alkanes in breath to monitor lipid peroxidation in the presence of volatile toxicants and metabolites. An optimized automatic method.
    Frank H, Dürk H.
    Arch Toxicol 53, 213 - 223 (1983).